Rec no.,TA ID,Year of Publication,Process,Technology,Technology type,Indication,Categorisation (for specific recommendation),Comment
3,TA003,2000/01,MTA,Paclitaxel,Pharmaceutical,Ovarian cancer,Recommended,Guidance has been replaced by TA55. Recommendation in line with marketing authorisation.
5,TA005,2000/01,MTA,Liquid Based Cytology (LBC),Other therapeutic therapies,Cervical cancer,Only in Research,"Guidance has been replaced by TA69. At the time of appraisal the Committee advised that there was insufficient evidence to justify the nationwide introduction of LBC technology. However they recommended that large-scale pilot implementation studies should be carried out to evaluate the effectiveness, costs and practical implications of the introduction of LBC technology into the cervical screening programme.  "
6,TA006,2000/01,MTA,Docetaxel,Pharmaceutical,Advanced breast cancer,Recommended,Guidance has been replaced by TA30. Recommendation in line with marketing authorisation.
7,TA006,2000/01,MTA,Paclitaxel,Pharmaceutical,Advanced breast cancer,Recommended,Guidance has been replaced by TA30. Recommendation in line with marketing authorisation.
27,TA017,2000/01,MTA,Laparoscopic surgery ,Surgical procedure,Colorectal cancer ,Only in Research,Guidance replaced by TA105. At the time of appraisal it was recommended that laparoscopic surgery for colorectal cancer should be limited to use in a randomised controlled trial setting.
35,TA023,2001/02,MTA,Temozolomide,Pharmaceutical,Brain cancer (recurrent),Recommended,Recommendation in line with marketing authorisation. 
42,TA025,2001/02,MTA,Gemcitabine (1st line),Pharmaceutical,Pancreatic cancer ,Recommended,Recommended in line with clinical practice. 
43,TA025,2001/02,MTA,Gemcitabine (2nd line),Pharmaceutical,Pancreatic cancer ,Not Recommended,At the time of appraisal there was insufficient evidence to support the use of gemcitabine as a second-line treatment in patients with pancreatic adenocarcinoma.
44,TA026,2001/02,MTA,Docetaxel (2nd line),Pharmaceutical,Non-small cell lung cancer ,Recommended,Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
45,TA026,2001/02,MTA,Gemcitabine (1st line),Pharmaceutical,Non-small cell lung cancer ,Recommended,Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
46,TA026,2001/02,MTA,Paclitaxel (1st line),Pharmaceutical,Non-small cell lung cancer ,Recommended,Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
47,TA026,2001/02,MTA,Vinorelbine (1st line),Pharmaceutical,Non-small cell lung cancer ,Recommended,Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
52,TA028,2001/02,MTA,Topotecan (2nd and subsequent lines of treatment),Pharmaceutical,Advanced ovarian cancer ,Recommended,Guidance has been replaced by TA91. Recommendation in line with marketing authorisation.
53,TA029,2001/02,MTA,Fludarabine -  Intravenous formulation (2nd line),Pharmaceutical,Leukaemia (B-cell chronic lymphocytic),Recommended,Recommendation in line with marketing authorisation.
54,TA029,2001/02,MTA,Fludarabine - Oral formulation (2nd line),Pharmaceutical,Leukaemia (B-cell chronic lymphocytic),Recommended,Recommendation in line with marketing authorisation.
55,TA030,2001/02,MTA,Docetaxel (2nd line),Pharmaceutical,Advanced breast cancer ,Recommended,Update of guidance TA6. Guidance has been incorporated in   CG81. Recommendation in line with marketing authorisation.
56,TA030,2001/02,MTA,Docetaxel in combination with an anthracycline (1st line),Pharmaceutical,Advanced breast cancer ,Not Recommended,"Update of guidance TA6. Guidance has been incorporated in CG81. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
57,TA030,2001/02,MTA,Paclitaxel (2nd line),Pharmaceutical,Advanced breast cancer ,Recommended,Update of guidance TA6. Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
61,TA033,2001/02,MTA,Irinotecan in combination with 5-fluorouracil and folinic acid (5FU/FA) (1st-line),Pharmaceutical,Colorectal cancer (advanced),Not Recommended,"Guidance replaced by TA93. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
62,TA033,2001/02,MTA,Irinotecan monotherapy (2nd line),Pharmaceutical,Colorectal cancer (advanced),Recommended,Guidance replaced by TA93. Recommendation in line with marketing authorisation.
63,TA033,2001/02,MTA,Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA) (1st-line),Pharmaceutical,Colorectal cancer (advanced),Optimised,Guidance has been replaced by TA93. Optimised recommendation for use in specific circumstances in patients with advanced colorectal cancer in patients with metastases that are confined solely to the liver and may become resectable (‘down staged’) following treatment. 
64,TA033,2001/02,MTA,Raltitrexed,Pharmaceutical,Colorectal cancer (advanced),Only in Research,"Guidance replaced by TA93. At the time of appraisal, the Committee concluded from the available evidence that the need for rigorous monitoring and possibility of increased mortality outweigh any benefits of convenience of administration with raltitrexed. Therefore the technology was only recommended for use in the context of appropriately designed clinical trials."
65,TA034,2001/02,MTA,Trastuzumab in combination with paclitaxel,Pharmaceutical,Breast cancer,Recommended,Recommendation in line with marketing authorisation.
66,TA034,2001/02,MTA,Trastuzumab monotherapy,Pharmaceutical,Breast cancer,Recommended,Recommendation in line with marketing authorisation.
70,TA037,2001/02,MTA,Rituximab (3rd and subsequent lines of treatment),Pharmaceutical,Lymphoma (follicular non-Hodgkin's) ,Not recommended,"Guidance replaced by TA137.  At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
71,TA037,2001/02,MTA,Rituximab (last line),Pharmaceutical,Lymphoma (follicular non-Hodgkin's) ,Only in Research,"Guidance replaced by TA137. At the time of appraisal, the technology was only recommended for last-line therapy in the context of the construction of a case series of past and new patients, to determine with more certainty its effectiveness in this indication."
89,TA045,2002/03,MTA,Pegylated liposomal doxorubicin hydrochloride (PLDH) ,Pharmaceutical,Ovarian cancer (advanced),Recommended,Guidance has been replaced by TA91. Recommendation in line with marketing authorisation.
98,TA050,2002/03,MTA,Imatinib,Pharmaceutical,Leukaemia (CML),Recommended,Guidance has been replaced by TA70. Recommendation in line with marketing authorisation.
111,TA054,2002/03,MTA,Vinorelbine combination therapies,Pharmaceutical,Breast cancer,Not Recommended,"Guidance has been incorporated in CG81. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
112,TA054,2002/03,MTA,Vinorelbine monotherapy,Pharmaceutical,Breast cancer,Recommended,Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
113,TA055,2002/03,MTA,Paclitaxel (1st line),Pharmaceutical,Ovarian cancer ,Recommended,Update of guidance TA3. Recommendation in line with marketing authorisation.
114,TA055,2002/03,MTA,Paclitaxel (2nd line),Pharmaceutical,Ovarian cancer ,Recommended,"Update of guidance TA3. Recommendation in line with clinical practice. In view of the limited evidence available on the clinical effectiveness of paclitaxel as a second-line treatment, the Committee concluded that paclitaxel should be considered as an option for second-line treatment only for women who do not receive it as part of their first-line therapy. For such women, it should be offered alongside other drugs that are licensed for second-lien treatment of ovarian cancer."
123,TA061,2003/04,MTA,Capecitabine,Pharmaceutical,Colorectal cancer,Recommended,Recommendation in line with marketing authorisation.
124,TA061,2003/04,MTA,Tegafur with uracil,Pharmaceutical,Colorectal cancer,Recommended,Recommendation in line with marketing authorisation.
125,TA062,2003/04,MTA,Capecitabine,Pharmaceutical,Breast cancer (locally advanced or metastatic),Recommended,Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
126,TA062,2003/04,MTA,"Capecitabine, plus docetaxel",Pharmaceutical,Breast cancer (locally advanced or metastatic),Recommended,Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
132,TA065,2003/04,MTA,Rituximab,Pharmaceutical,Non-Hodgkin's lymphoma - stage II - IV,Recommended,Recommendation in line with marketing authorisation.
133,TA065,2003/04,MTA,Rituximab,Pharmaceutical,Non-Hodgkin's lymphoma - stage I,Only in Research,"At the time of appraisal, the clinical and cost-effectiveness of rituximab in patients with localised (stage 1) disease had not been established. Therefore use in these circumstances was only recommended as part of ongoing or new clinical studies.  "
139,TA069,2003/04,MTA,Liquid Based Cytology (LBC),Other therapeutic therapies,Cervical cancer,Recommended,Update of guidance TA5. Moved to static list in 2007. Recommendation in line with clinical practice.
140,TA070,2003/04,MTA,Imatinib,Pharmaceutical,Leukaemia (CML),Recommended,Update of guidance TA50. Guidance has been partially updated by TA241 and TA251. Recommendation in line with marketing authorisation.
194,TA086,2004/05,MTA,Imatinib,Pharmaceutical,"Gastrointestinal stromal tumours (unresectable, metastatic)",Recommended,Guidance has been partially updated by TA209. Recommendation in line with marketing authorisation.
204,TA091,2005/06,MTA,Pegylated liposomal doxorubicin hydrochloride (PLDH),Pharmaceutical,Ovarian cancer (advanced),Recommended,Recommendation in line with marketing authorisation. 
205,TA091,2005/06,MTA,Topotecan,Pharmaceutical,Ovarian cancer (advanced),Recommended,Recommendation in line with marketing authorisation. 
206,TA091,2005/06,MTA,Paclitaxel,Pharmaceutical,Ovarian cancer (advanced),Recommended,Update of guidance TA45. Recommendation in line with marketing authorisation. 
207,TA091,2005/06,MTA,Paclitaxel in combination with a platinum-based compound,Pharmaceutical,Ovarian cancer (advanced),Recommended,"Update of guidance TA28. Recommendation in line with clinical practice for women in whom PLDH and single-agent paclitaxel are considered inappropriate because they have previously been exposed to PLDH and single-agent paclitaxel, or if the impact of the adverse effects of treatment with these drugs is considered unacceptable. "
209,TA093,2005/06,MTA,Irinotecan,Pharmaceutical,Colorectal cancer (advanced),Recommended,Update of guidance TA33. Recommendation in line with marketing authorisation.
210,TA093,2005/06,MTA,Irinotecan in combination with 5-fluorouracil and folinic acid,Pharmaceutical,Colorectal cancer (advanced),Recommended,Update of guidance TA33. Recommendation in line with marketing authorisation.
211,TA093,2005/06,MTA,Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA),Pharmaceutical,Colorectal cancer (advanced),Recommended,Update of guidance TA33. Recommendation in line with marketing authorisation.
212,TA093,2005/06,MTA,Raltitrexed,Pharmaceutical,Colorectal cancer (advanced),Only in Research,"Update of guidance TA33. At the time of appraisal, the Committee concluded from the available evidence that the need for rigorous monitoring and possibility of increased mortality outweigh any benefits of convenience of administration with raltitrexed. Therefore the technology was only recommended for use in the context of appropriately designed clinical trials. "
237,TA100,2006/07,MTA,Capecitabine (adjuvant),Pharmaceutical,Colon cancer ,Recommended,Recommendation in line with marketing authorisation. Moved to static list.
238,TA100,2006/07,MTA,Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA) (adjuvant),Pharmaceutical,Colon cancer ,Recommended,Recommendation in line with marketing authorisation. Moved to static list.
239,TA101,2006/07,MTA,Docetaxel,Pharmaceutical,Prostate cancer (hormone-refractory),Recommended,Recommendation in line with marketing authorisation.
246,TA105,2006/07,MTA,Laparoscopic resection,Surgical procedure,Colorectal cancer,Recommended,Update of guidance TA17. Recommendation in line with clinical practice.  
249,TA107,2006/07,STA,Trastuzumab,Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.  
250,TA108,2006/07,STA,Paclitaxel,Pharmaceutical,Breast cancer (early),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
251,TA109,2006/07,STA,Docetaxel with doxorubicin and cyclophosphamide (the TAC regimen),Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
252,TA110,2006/07,STA,Rituximab,Pharmaceutical,Follicular lymphoma,Recommended,Guidance has been replaced by TA243. Recommendation in line with marketing authorisation.
257,TA112,2006/07,MTA,Anastrozole,Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
258,TA112,2006/07,MTA,Exemestane,Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
259,TA112,2006/07,MTA,Letrozole,Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
264,TA116,2006/07,STA,Gemcitabine,Pharmaceutical,Breast cancer,Recommended,Recommendation in line with marketing authorisation.
266,TA118,2006/07,MTA,Bevacizumab in combination with 5-fluorouracil plus folinic acid (with or without irinotecan),Pharmaceutical,Colorectal cancer (metastatic),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
267,TA118,2006/07,MTA,Cetuximab in combination with irinotecan,Pharmaceutical,Colorectal cancer (metastatic),Not Recommended,"Guidance has been partially replaced by TA242. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
268,TA119,2006/07,STA,Fludarabine (monotherapy),Pharmaceutical,Leukaemia (lymphocytic),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
271,TA121,2007/08,MTA,Carmustine implants,Pharmaceutical,Glioma (newly diagnosed),Recommended,Recommendation in line with clinical practice.
272,TA121,2007/08,MTA,Temozolomide,Pharmaceutical,Glioma (newly diagnosed),Recommended,Recommendation in line with clinical practice.
275,TA124,2007/08,STA,Pemetrexed (2nd line),Pharmaceutical,Non-small cell lung cancer ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
280,TA129,2007/08,STA,Bortezomib,Pharmaceutical,Multiple myeloma,Recommended,Recommended after agreement of Patient Access Scheme.
292,TA135,2007/08,MTA,Pemetrexed disodium,Pharmaceutical,Malignant pleural mesothelioma,Recommended,Recommendation in line with clinical practice. 
294,TA137,2007/08,STA,Rituximab (3rd line),Pharmaceutical,Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,Recommended,Update of guidance TA37. Recommendation in line with marketing authorisation. 
305,TA145,2008/09,STA,Cetuximab,Pharmaceutical,Locally advanced squamous cell cancer of the head and neck,Optimised,Optimised recommendation for use in specific circumstances for people with locally advanced squamous cell cancer of the head and neck whose Karnofsky performance-status score is 90% or greater and for whom all forms of platinum-based chemoradiotherapy treatment are contraindicated. 
307,TA147,2008/09,STA,Bevacizumab (1st line),Pharmaceutical,Metastatic breast cancer ,Terminated Appraisal - non submission,Guidance has been replaced by TA214. The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
308,TA148,2008/09,STA,Bevacizumab (1st line),Pharmaceutical,"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer ",Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
309,TA149,2008/09,STA,Carmustine implants,Pharmaceutical,Recurrent  glioblastoma multiforme,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
310,TA150,2008/09,STA,Cetuximab (2nd-3rd line),Pharmaceutical,Metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy,Terminated Appraisal - non submission,Guidance has been replaced by TA242. The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
335,TA162,2008/09,STA,Erlotinib (2nd-line treatment in patients for whom docetaxel is suitable),Pharmaceutical,Non-small-cell lung cancer,Recommended,Recommendation in line with marketing authorisation and following agreement of a Patient Access Scheme.
336,TA162,2008/09,STA,Erlotinib (2nd-line treatment in patients for whom docetaxel is unsuitable; or as a 3rd-line treatment after docetaxel therapy),Pharmaceutical,Non-small-cell lung cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
349,TA169,2008/09,MTA,Sunitinib (1st line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Recommended,Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
351,TA171,2009/10,STA,Lenalidomide,Pharmaceutical,Multiple  myeloma ,Recommended,Recommended following agreement on Patient Access Scheme.
352,TA172,2009/10,STA,Cetuximab,Pharmaceutical,Recurrent  and/or metastatic squamous cell cancer of the head and neck,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
354,TA174,2009/10,STA,Rituximab in combination with fludarabine and cyclophosphamide (1st line),Pharmaceutical,Chronic lymphocytic leukaemia ,Optimised,Optimised recommendation for use in specific circumstances in combination with fludarabine and cyclophosphamide. 
355,TA175,2009/10,STA,Gefitinib (2nd line),Pharmaceutical,Locally advanced or metastatic non-small-cell-lung cancer ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
356,TA176,2009/10,STA,"Cetuximab in combination with 5-fluorouracil (5-FU), folinic acid and oxaliplatin (FOLFOX) (1st line)",Pharmaceutical,Metastatic colorectal cancer ,Recommended,Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
357,TA176,2009/10,STA,"Cetuximab in combination with 5-FU, folinic acid and irinotecan (FOLFIRI) (1st line)",Pharmaceutical,Metastatic colorectal cancer ,Recommended,Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
359,TA178,2009/10,MTA,Bevacizumab (1st line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
360,TA178,2009/10,MTA,Sorafenib (1st line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
361,TA178,2009/10,MTA,Temsirolimus (1st line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
362,TA178,2009/10,MTA,Sunitinib (2nd line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
363,TA178,2009/10,MTA,Sorafenib (2nd line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
364,TA179,2009/10,STA,Sunitinib,Pharmaceutical,Unresectable and/or metastatic malignant gastrointestinal stromal tumours,Recommended,Recommendation in line with marketing authorisation and following agreement of Patient Access Scheme.
366,TA181,2009/10,STA,Pemetrexed in combination with cisplatin (1st line),Pharmaceutical,Locally advanced or metastatic non-small-cell lung cancer ,Recommended,Recommendation in line with clinical practice.
368,TA183,2009/10,STA,Topotecan in combination with cisplatin,Pharmaceutical,Recurrent or stage IV cervical cancer ,Recommended,Recommended in line with marketing authorisation.
369,TA184,2009/10,MTA,Oral topotecan ,Pharmaceutical,Relapsed small-cell lung cancer,Recommended,Recommendation in line with clinical practice.
370,TA184,2009/10,MTA,Intravenous topotecan,Pharmaceutical,Relapsed small-cell lung cancer ,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
371,TA185,2009/10,STA,Intravenous trabectedin,Pharmaceutical,Advanced soft tissue sarcoma ,Recommended,Recommended following agreement of Patient Access Scheme.
378,TA189,2010/11,STA,Sorafenib (1st line),Pharmaceutical,Advanced and metastatic hepatocellular carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
379,TA190,2010/11,STA,Pemetrexed (maintenance treatment),Pharmaceutical,Non-small-cell lung cancer,Recommended,Recommendation in line with marketing authorisation. 
380,TA191,2010/11,STA,Capecitabine (1st line),Pharmaceutical,Inoperable advanced gastric cancer,Recommended,Recommendation in line with marketing authorisation
381,TA192,2010/11,STA,Gefitinib (1st line),Pharmaceutical,Locally advanced or metastatic non-small-cell lung cancer,Recommended,Recommendation in line with marketing authorisation and following agreement of Patient Access Scheme.
382,TA193,2010/11,STA,Rituximab in combination with chemotherapy (other than fludarabine and cyclophosphamide),Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia,Only in Research,"Due to a lack of clinical and cost effectiveness evidence, the Committee concluded that rituximab plus chemotherapy (other than fludarabine and cyclophosphamide) should only be used for the treatment of relapsed or refractory chronic lymphocytic leukaemia in the context of research."
383,TA193,2010/11,STA,Rituximab in combination with fludarabine and cyclophosphamide,Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for use in specific circumstances for the treatment of people who have not previously received rituximab (or who have only received rituximab in the context of a clinical trial at a dose lower than the licensed dose for chronic lymphocytic leukaemia, or in combination with chemotherapy other than fludarabine and cyclophosphamide) and whose disease is not refractory to fludarabine."
384,TA193,2010/11,STA,Rituximab in combination with fludarabine and cyclophosphamide,Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia,Only in Research,"For patients who have already received rituximab (in circumstances other than in the context of a clinical trial), rituximab in combination with fludarabine and cyclophosphamide should only be used in the context of research."
385,TA194,2010/11,STA,Denosumab,Pharmaceutical,Therapy-induced bone loss in non-metastatic prostate cancer,Terminated Appraisal - non submission,Guidance has been replaced by CG175The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
393,TA196,2010/11,STA,Imatinib adjuvant,Pharmaceutical,Gastrointestinal stromal tumours (resectable),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
402,TA202,2010/11,STA,Ofatumumab,Pharmaceutical,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available and the proposed Patient Access Scheme."
409,TA206,2010/11,STA,Bendamustine,Pharmaceutical,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
410,TA207,2010/11,STA,Temsirolimus,Pharmaceutical,Mantle cell lymphoma (relapsed) ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
411,TA208,2010/11,STA,Trastuzumab in combination with cisplatin and capecitabine or 5-fluorouracil,Pharmaceutical,"Gastric cancer (HER2-positive, metastatic)",Optimised,Optimised recommendation for use under specific circumstances for people with human epidermal growth factor receptor 2 (HER2)-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior treatment for their metastatic disease and have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3 (IHC3 positive). 
412,TA209,2010/11,MTA,Imatinib (dose escalation to 600mg/day or 800mg/day following disease progression on 400 mg/day imatinib),Pharmaceutical,"Gastrointestinal stromal tumours (unresectable, metastatic)",Not Recommended,"Partial update of guidance TA86 (recommendation 1.4). At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
420,TA212,2010/11,STA,Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine,Pharmaceutical,Metastatic colorectal cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
422,TA214,2010/11,STA,Bevacizumab in combination with a taxane (1st line),Pharmaceutical,Metastatic breast cancer,Not Recommended,"Update of guidance TA147. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
423,TA215,2010/11,STA,Pazopanib (1st line),Pharmaceutical,Metastatic renal cell carcinoma,Recommended,Recommended in line with clinical practice and after agreement of Patient Access Scheme.
424,TA216,2010/11,STA,Bendamustine (1st line),Pharmaceutical,Chronic lymphocytic leukaemia (Binet stage B or C),Recommended,Recommendation in line with marketing authorisation.
430,TA218,2010/11,STA,Azacitidine,Pharmaceutical,"Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia",Recommended,Recommendation in line with marketing authorisation and after agreement of Patient Access Scheme.
431,TA219,2011/12,STA,Everolimus,Pharmaceutical,Advanced renal cell carcinoma (2nd line),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
434,TA222,2011/12,STA,Trabectedin in combination with pegylated liposomal doxorubicin hydrochloride,Pharmaceutical,Relapsed platinum-sensitive ovarian cancer in women,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
442,TA226,2011/12,STA,Rituximab (1st line maintenance treatment),Pharmaceutical,Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,Recommended,Recommended in line with marketing authorisation.
443,TA227,2011/12,STA,Erlotinib (1st line maintenance treatment),Pharmaceutical,Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available, despite agreement of a patient access scheme."
444,TA228,2011/12,MTA,Thalidomide in combination with an alkylating agent and a corticosteroid,Pharmaceutical,Multiple myeloma,Recommended,Recommended in line with marketing authorisation.
445,TA228,2011/12,MTA,Bortezomib in combination with an alkylating agent and a corticosteroid,Pharmaceutical,Multiple myeloma,Optimised,Optimised recommendation for use in specific circumstances for people with multiple myeloma if high-dose chemotherapy with stem cell transplantation is considered inappropriate and they are unable to tolerate or have contraindications to thalidomide. 
453,TA235,2011/12,STA,Mifamurtide,Pharmaceutical,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
458,TA239,2011/12,STA,Fulvestrant,Pharmaceutical,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
459,TA240,2011/12,STA,Panitumumab in combination with chemotherapy,Pharmaceutical,Treatment of metastatic colorectal cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
460,TA241,2011/12,MTA,Nilotinib,Pharmaceutical,Treatment of chronic or accelerated phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults whose CML is resistant to treatment with standard-dose imatinib or who have imatinib intolerance,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
461,TA241,2011/12,MTA,Dasatinib,Pharmaceutical,"Treatment of chronic, accelerated or blast-crisis phase CML in adults with imatinib intolerance or whose CML is resistant to treatment with standard-dose imatinib",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
462,TA241,2011/12,MTA,High dose imatinib,Pharmaceutical,"Treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
463,TA242,2011/12,MTA,Cetuximab monotherapy or combination chemotherapy,Pharmaceutical,Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy,Not Recommended,The guidance updates and replaces recommendations in TA150. This guidance also partially updates recommendations TA118. 
464,TA242,2011/12,MTA,Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy,Pharmaceutical,Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
465,TA242,2011/12,MTA,Panitumumab monotherapy,Pharmaceutical,Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
466,TA243,2011/12,MTA,Rituximab in combination with chemotherapy,Pharmaceutical,First-line treatment of stage III-IV follicular lymphoma,Recommended,This guidance updates and replaces TA110. Recommendation in line with marketing authorisation.
474,TA250,2012/13,STA,Eribulin,Pharmaceutical,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available despite agreement of a patient access scheme."
475,TA251,2012/13,MTA,Standard-dose imatinib (400mg/day),Pharmaceutical,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia ,Recommended,Partially updates TA70. Recommended in line with marketing authorisation.
476,TA251,2012/13,MTA,Nilotinib,Pharmaceutical,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia ,Recommended,Recommended in line with marketing authorisation and following agreement of PAS.
477,TA251,2012/13,MTA,Dasatinib,Pharmaceutical,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia ,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available"
481,TA255,2012/13,STA,Cabazitaxel in combination with prednisone or prednisolone,Pharmaceutical,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
483,TA257,2012/13,MTA,Lapatinib in combination with an aromatase inhibitor (1st line),Pharmaceutical,Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
484,TA257,2012/13,MTA,Trastuzumab in combination with an aromatase inhibitor (1st line),Pharmaceutical,Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
485,TA258,2012/13,STA,Erlotinib (1st line),Pharmaceutical,Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
486,TA259,2012/13,STA,Abiraterone in combination with prednisolone or prednisone (2nd line),Pharmaceutical,Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
490,TA263,2012/13,STA,Bevacizumab in combination with capecitabine (1st line),Pharmaceutical,First-line treatment of metastatic breast cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
492,TA265,2012/13,MTA,Denosumab,Pharmaceutical,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,Recommended,Recommended in line with clinical practice following agreement of patient access scheme.
493,TA265,2012/13,MTA,Denosumab,Pharmaceutical,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available despite agreement of a patient access scheme."
496,TA268,2012/13,STA,Ipilimumab,Pharmaceutical,Previously treated advanced (unresectable or metastatic) melanoma  ,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
497,TA269,2012/13,STA,Vemurafenib,Pharmaceutical,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma  ,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
498,TA270,2012/13,STA,Decitabine,Pharmaceutical,Acute myeloid leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
500,TA272,2012/13,STA,Vinflunine,Pharmaceutical,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
515,TA284,2013/14,STA,Bevacizumab in combination with paclitaxel and carboplatin,Pharmaceutical,Advanced ovarian cancer (1st line),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
516,TA285,2013/14,STA,Bevacizumab in combination with gemcitabine and carboplatin,Pharmaceutical,First recurrence of platinum-sensitive advanced ovarian cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
522,TA289,2013/14,STA,Ruxolitinib,Pharmaceutical,Disease-related splenomegaly or symptoms in adults with myelofibrosis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
528,TA295,2013/14,STA,Everolimus in combination with exemestane,Pharmaceutical,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
529,TA296,2013/14,STA,Crizotinib,Pharmaceutical,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
532,TA299,2013/14,STA,Bosutinib,Pharmaceutical,Previously treated chronic myeloid leukaemia,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Guidance has been replaced."
540,TA306,2013/14,STA,Pixantrone monotherapy,Pharmaceutical,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,Optimised,Optimised recommendation for treating adults with multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma only if: the person has previously been treated with rituximab and the person is receiving third- or fourth-line treatment and the manufacturer provides pixantrone with the discount agreed in the patient access scheme.
541,TA307,2013/14,STA,Aflibercept in combination with irinotecan and fluorouracil-based therapy,Pharmaceutical,Metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
543,TA309,2014/15,STA,Pemetrexed,Pharmaceutical,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
544,TA310,2014/15,STA,Afatinib,Pharmaceutical,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
545,TA311,2014/15,STA,"Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide",Pharmaceutical,For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,Recommended,Recommended in line with marketing authorisation.
553,TA316,2014/15,STA,Enzalutamide,Pharmaceutical,Metastatic hormone-relapsed prostate cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
556,TA319,2014/15,STA,Ipilimumab,Pharmaceutical,Previously untreated advanced (unresectable or metastatic) melanoma,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
558,TA321,2014/15,STA,Dabrafenib,Pharmaceutical,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
559,TA322,2014/15,STA,Lenalidomide,Pharmaceutical,Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
560,TA323,2014/15,MTA,"Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa)",Pharmaceutical,Treating anaemia in people with cancer having chemotherapy ,Recommended,Recommended in line with marketing authorisation
563,TA326,2014/15,STA,Imatinib,Pharmaceutical,Adjuvant treatment of gastrointestinal stromal tumours ,Recommended,Recommended in line with clinical practice
565,TA328,2014/15,STA,Idelalisib,Pharmaceutical,follicular lymphoma that is refractory to 2 prior treatments,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
571,TA332,2014/15,STA,Sipuleucel-T,Pharmaceutical,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.  This guidance has been withdrawn after publication, because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015."
572,TA333,2014/15,STA,Axitinib,Pharmaceutical,treating advanced renal cell carcinoma after failure of prior systemic treatment,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
573,TA334,2014/15,STA,Regorafenib,Pharmaceutical,Metastatic colorectal cancer after treatment for metastatic disease,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
579,TA338,2014/15,STA,Pomalidomide in combination with dexamethasone,Pharmaceutical,Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
584,TA343,2015/16,STA,Obinutuzumab in combination with chlorambucil,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for obinutuzumab in combination with chlorambucil as an option for adults with untreated chronic lymphocytic leukaemia who have comorbidities that make full‑dose fludarabine‑based therapy unsuitable for them, only if: bendamustine‑based therapy is not suitable 

and the company provides obinutuzumab with the discount agreed in the patient access scheme.
"
585,TA344,2015/16,STA,Ofatumumab in combination with chlorambucil,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
588,TA347,2015/16,STA,Nintedanib in combination with docetaxel ,Pharmaceutical,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
594,TA353,2015/16,STA,Bevacizumab,Pharmaceutical,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
598,TA357,2015/16,STA,Pembrolizumab,Pharmaceutical,Treating advanced melanoma after disease progression with ipilimumab,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
600,TA359,2015/16,STA,Idelalisib in combination with rituximab,Pharmaceutical,Treating chronic lymphocytic leukaemia,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme. Note: no evidence presented for population not recommended.
601,TA360,2015/16,STA,Paclitaxel as albumin‑bound nanoparticles in combination with gemcitabine,Pharmaceutical,Previously untreated metastatic pancreatic cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
603,TA362,2015/16,STA,Paclitaxel as albumin-bound nanoparticles with carboplatin,Pharmaceutical,Untreated non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
611,TA366,2015/16,STA,Pembrolizumab,Pharmaceutical,Advanced melanoma not previously treated with ipilimumab,Recommended,"Recommended in line with marketing authorisation and following agreement of patient access scheme. Note: The MA was appraised across 2 separate appraisals, both recommended (see TA357)."
615,TA370,2015/16,STA,Bortezomib,Pharmaceutical,Previously untreated mantle cell lymphoma,Recommended,Recommended in line with marketing authorisation
616,TA371,2015/16,STA,Trastuzumab emtansine,Pharmaceutical,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
622,TA374,2015/16,MTA,Erlotinib,Pharmaceutical,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,Optimised,"Optimised recommendation for erlotinib, only if the company provides erlotinib with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 258: Erlotinib is recommended as an option for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed in people who have had non‑targeted chemotherapy because of delayed confirmation that their tumour is epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation‑positive. Erlotinib is recommended as an option for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed after non‑targeted chemotherapy in people with tumours of unknown EGFR‑TK mutation status, only if: the result of an EGFR‑TK mutation diagnostic test is unobtainable because of an inadequate tissue sample or poor‑quality DNA and the treating clinician considers that the tumour is very likely to be EGFR‑TK mutation‑positive and the person's disease responds to the first 2 cycles of treatment with erlotinib. Erlotinib is not recommended for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed after non‑targeted chemotherapy in people with tumours that are EGFR‑TK mutation‑negative."
623,TA374,2015/16,MTA,Gefitinib,Pharmaceutical,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
631,TA376,2015/16,STA,Radium-223 dichloride,Pharmaceutical,Treating hormone-relapsed prostate cancer with bone metastases,Optimised,"Optimised recommendation for Radium‑223 dichloride as an option for treating adults with hormone‑relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, only if:

• they have had treatment with docetaxel, and 

• the company provides radium‑223 dichloride with the discount agreed in the patient access scheme."
632,TA377,2015/16,STA,Enzalutamide,Pharmaceutical,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
633,TA378,2015/16,STA,Ramucirumab alone or with paclitaxel,Pharmaceutical,Treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
635,TA380,2015/16,STA,Panobinostat in combination with bortezomib and dexamethasone,Pharmaceutical,Treating multiple myeloma after at least 2 previous treatments,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
636,TA381,2015/16,STA,Olaparib,Pharmaceutical,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",Optimised,"Optimised recommendation for olaparib as an option for treating adults with relapsed, platinum‑sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum‑based chemotherapy only if:
they have had 3 or more courses of platinum-based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months will be met by the company."
643,TA384,2015/16,STA,Nivolumab,Pharmaceutical,Advanced (unresectable or metastatic) melanoma,Recommended,Recommended in line with marketing authorisation.
646,TA386,2015/16,STA,Ruxolitinib,Pharmaceutical,Treating disease-related splenomegaly or symptoms in adults with myelofibrosis,Optimised,"Optimised recommendation for ruxolitinib for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only:
•in people with intermediate‑2 or high-risk disease, and
•if the company provides ruxolitinib with the discount agreed in the patient access scheme."
647,TA387,2016/17,STA,Abiraterone in combination with prednisone or prednisolone,Pharmaceutical,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,Recommended,"Recommended in line with the marketing authorisation, only if the company rebates the drug cost of abiraterone from the 11th month until the end of treatment for people who remain on treatment for more than 10 months."
649,TA389,2016/17,MTA,Paclitaxel in combination with platinum or as monotherapy,Pharmaceutical,Treating recurrent ovarian cancer,Recommended,Recommended in line with marketing authorisation.
650,TA389,2016/17,MTA,Pegylated liposomal doxorubicin hydrochloride (PLDH) monotherapy,Pharmaceutical,Treating recurrent ovarian cancer,Recommended,Recommended in line with marketing authorisation.
651,TA389,2016/17,MTA,PLDH in combination with platinum,Pharmaceutical,Treating recurrent ovarian cancer,Recommended,Recommended in line with clinical practice. The use of PLDH (Caelyx) in combination with platinum is outside the terms of the marketing authorisation. Consequently the statutory funding requirement does not apply to this recommendation.
652,TA389,2016/17,MTA,Gemcitabine in combination with carboplatin ,Pharmaceutical,Treating recurrent ovarian cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
653,TA389,2016/17,MTA,Trabectedin in combination with PLDH,Pharmaceutical,Treating recurrent ovarian cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
654,TA389,2016/17,MTA,Topotecan,Pharmaceutical,Treating recurrent ovarian cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
658,TA391,2016/17,STA,Cabazitaxel in combination with prednisone or prednisolone,Pharmaceutical,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
662,TA395,2016/17,STA,Ceritinib,Pharmaceutical,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
663,TA396,2016/17,STA,Trametinib in combination with dabrafenib,Pharmaceutical,Treating unresectable or metastatic melanoma,Recommended,Recommended in line with marketing authorisation
666,TA399,2016/17,STA,Azacitidine,Pharmaceutical,Treating acute myeloid leukaemia with more than 30% bone marrow blasts,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
667,TA400,2016/17,STA,Nivolumab in combination with ipilimumab,Pharmaceutical,Treating advanced melanoma,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
668,TA401,2016/17,STA,Bosutinib,Pharmaceutical,Previously treated chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
669,TA402,2016/17,STA,Pemetrexed,Pharmaceutical,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
670,TA403,2016/17,STA,Ramucirumab in combination with docetaxel,Pharmaceutical,Previously treated locally advanced or metastatic non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
671,TA404,2016/17,STA,Degarelix,Pharmaceutical,Advanced hormone-dependent prostate cancer,Optimised,"Optimised recommendation for degarelix as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016."
672,TA405,2016/17,STA,Trifluridine–tipiracil,Pharmaceutical,Previously treated metastatic colorectal cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
673,TA406,2016/17,STA,Crizotinib,Pharmaceutical,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
675,TA408,2016/17,STA,"Pegaspargase, as part of antineoplastic combination therapy",Pharmaceutical,Treating acute lymphoblastic leukaemia,Optimised,"Optimised recommendation for pegaspargase, as part of antineoplastic combination therapy, ias an option for treating acute lymphoblastic leukaemia in children, young people and adults only when they have untreated newly diagnosed disease."
677,TA410,2016/17,STA,Talimogene laherparepvec,Pharmaceutical,Treating unresectable metastatic melanoma,Optimised,"Optimised recommendation for talimogene laherparepvec an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if:
·         treatment with systemically administered immunotherapies is not suitable and
·         the company provides talimogene laherparepvec with the discount agreed in the patient access scheme."
678,TA411,2016/17,STA,"Necitumumab, in combination with gemcitabine and cisplatin",Pharmaceutical,Untreated advanced or metastatic squamous non-small-cell lung cancer ,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
679,TA412,2016/17,STA,Radium‑223 dichloride,Pharmaceutical,Treating hormone-relapsed prostate cancer with bone metastases,Optimised,"Optimised recommendation for radium‑223 dichloride as an option for treating hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases in adults, only if:
they have already had docetaxel or
docetaxel is contraindicated or is not suitable for them.
The drug is only recommended if the company provides radium‑223 dichloride with the discount agreed in the patient access scheme. "
681,TA414,2016/17,STA,Cobimetinib in combination with vemurafenib,Pharmaceutical,Unresectable or metastatic BRAF V600 mutation-positive melanoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
684,TA416,2016/17,STA,Osimertinib,Pharmaceutical,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,Recommended (CDF),Recommended in line with clinical practice for use within the Cancer Drugs fund only if the conditions in the managed access agreement for osimertinib are followed.
685,TA417,2016/17,STA,Nivolumab,Pharmaceutical,Previously treated advanced renal cell carcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
689,TA421,2016/17,STA,Everolimus in combination with exemestane,Pharmaceutical,Treating advanced breast cancer after endocrine therapy,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
690,TA422,2016/17,STA,Crizotinib,Pharmaceutical,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
691,TA423,2016/17,STA,Eribulin,Pharmaceutical,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,Optimised,"Optimised recommendation for eribulin as an option for treating locally advanced or metastatic breast cancer in adults, only when:
•it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine)
•the company provides eribulin with the discount agreed in the patient access scheme."
692,TA424,2016/17,STA,Pertuzumab in combination with trastuzumab and chemotherapy,Pharmaceutical,Neoadjuvant treatment of HER2-positive breast cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
693,TA425,2016/17,STA,Dasitinib,Pharmaceutical,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,Optimised,"Optimised recommendation for dasatinib as an option for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
• they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes."
694,TA425,2016/17,STA,Nilotinib,Pharmaceutical,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
695,TA425,2016/17,STA,High-dose imatinib,Pharmaceutical,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
696,TA426,2016/17,STA,Dasatinib,Pharmaceutical,Untreated chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
697,TA426,2016/17,STA,Nilotinib,Pharmaceutical,Untreated chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
698,TA426,2016/17,STA,Imatinib,Pharmaceutical,Untreated chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
699,TA427,2016/17,STA,"Pomalidomide, in combination with low‑dose dexamethasone",Pharmaceutical,Multiple myeloma previously treated with lenalidomide and bortezomib,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
700,TA428,2016/17,STA,Pembrolizumab,Pharmaceutical,PD-L1-positive non-small-cell lung cancer after chemotherapy,Optimised,"Optimised recommendation for pempbrolizumab for treating locally advanced or metastatic PD‑L1‑positive non‑small‑cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK]‑positive tumour), only if:
• pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression, and
• the company provides pembrolizumab with the discount agreed in the patient access scheme revised in the context of this appraisal."
701,TA429,2016/17,STA,Ibrutinib alone,Pharmaceutical,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
704,TA432,2016/17,STA,Everolimus,Pharmaceutical,Advanced renal cell carcinoma after previous treatment,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
706,TA434,2016/17,STA,Elotuzumab,Pharmaceutical,Previously treated multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
708,TA436,2016/17,STA,Bevacizumab,Pharmaceutical,EGFR mutation-positive non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
709,TA437,2016/17,STA,Ibrutinib with bendamustine and rituximab,Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy ,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
710,TA438,2016/17,STA,Alectinib,Pharmaceutical,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
711,TA439,2016/17,MTA,Cetuximab,Pharmaceutical,Previously untreated metastatic colorectal cancer,Recommended,Recommended in line with marketing authorisation.
712,TA439,2016/17,MTA,Panitumumab,Pharmaceutical,Previously untreated metastatic colorectal cancer,Recommended,Recommended in line with marketing authorisation.
713,TA440,2017/18,STA,Pegylated liposomal irinotecan in combination with 5‑fluorouracil and leucovorin,Pharmaceutical,Pancreatic cancer after gemcitabine,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
717,TA444,2017/18,STA,Afatinib,Pharmaceutical,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,Terminated appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
720,TA446,2017/18,STA,Brentuximab vedotin,Pharmaceutical,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,Optimised,"Optimised recommendation for brentuximab vedotin as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if:
•they have relapsed or refractory disease after autologous stem cell transplant and
•the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement."
721,TA446,2017/18,STA,Brentuximab vedotin,Pharmaceutical,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,Optimised (CDF),"Optimised recommendation for brentuximab vedotin for use within the Cancer Drugs Fund, as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if:

•they have relapsed or refractory disease after at least 2 previous therapies and 

•they cannot have autologous stem cell transplant or multi-agent chemotherapy and

•the conditions of the managed access agreement are followed."
722,TA447,2017/18,STA,Pembrolizumab,Pharmaceutical,Untreated PD-L1-positive metastatic non-small-cell lung cancer,Optimised (CDF),"Optimised recommendation for pembrolizumab for use within the Cancer Drugs Fund as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults only if:
•their tumours express PD-L1 with at least a 50% tumour proportion score and have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations
•pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression
•the conditions in the managed access agreement for pembrolizumab are followed"
724,TA449,2017/18,MTA,Everolimus,Pharmaceutical,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
725,TA449,2017/18,MTA,Sunitinib,Pharmaceutical,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,Recommended,Recommended in line with marketing authorisation.
726,TA450,2017/18,STA,Blinatumomab,Pharmaceutical,Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
727,TA451,2017/18,STA,Ponatinib,Pharmaceutical,Chronic myeloid leukaemia and acute lymphoblastic leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
728,TA452,2017/18,STA,Ibrutinib,Pharmaceutical,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
729,TA453,2017/18,STA,Bortezomib,Pharmaceutical,Multiple myeloma after second or subsequent relapse,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
730,TA454,2017/18,STA,Daratumumab,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
735,TA457,2017/18,STA,Carfilzomib in combination with dexamethasone,Pharmaceutical,Previously treated multiple myeloma,Optimised,"Optmised recommendation for carfilzomib in combination with dexamethasone as an option for treating multiple myeloma in adults, only if: 

•they have had only 1 previous therapy, which did not include bortezomib and
•the company provides carfilzomib with the discount agreed in the patient access scheme
"
736,TA458,2017/18,STA,Trastuzumab emtansine,Pharmaceutical,HER2-positive advanced breast cancer after trastuzumab and a taxane,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
741,TA462,2017/18,STA,Nivolumab ,Pharmaceutical,Relapsed or refractory classical Hodgkin lymphoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
742,TA463,2017/18,STA,Cabozantinib,Pharmaceutical,Previously treated advanced renal cell carcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
745,TA465,2017/18,STA,Olaratumab in combination with doxorubicin ,Pharmaceutical,Advanced soft tissue sarcoma,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for advanced soft tissue sarcoma in adults, only if:

•they have not had any previous systemic chemotherapy for advanced soft tissue sarcoma

•they cannot have curative treatment with surgery or their disease does not respond to radiotherapy

•the conditions in the managed access agreement for olaratumab are followed

"
752,TA469,2017/18,STA,Idelalisib with ofatumumab,Pharmaceutical,Chronic lymphocytic leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
753,TA470,2017/18,STA,Ofatumumab with chemotherapy ,Pharmaceutical,Chronic lymphocytic leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
755,TA472,2017/18,STA,Obinutuzumab with bendamustine,Pharmaceutical,Follicular lymphoma refractory to rituximab,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating adults with follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen, only if the conditions in the managed access agreement for obinutuzumab are followed."
756,TA473,2017/18,STA,Cetuximab in combination with platinum-based chemotherapy ,Pharmaceutical,Recurrent or metastatic squamous cell cancer of the head and neck,Optimised,"Optimised recommendation for cetuximab in combination with platinum-based chemotherapy as an option for treating recurrent or metastatic squamous cell cancer of the head and neck in adults only:
•if the cancer started in the oral cavity and
•when the company provides the drug in line with the commercial access agreement with NHS England.

"
757,TA474,2017/18,STA,Sorafenib,Pharmaceutical,Advanced hepatocellular carcinoma,Optimised,"Optmised recommendation for sorafenib only for people with Child-Pugh grade A liver impairment, only if the company provides sorafenib within the agreed commercial access arrangement."
759,TA476,2017/18,STA,Paclitaxel as albumin-bound nanoparticles (nab‑paclitaxel) with gemcitabine ,Pharmaceutical,Untreated metastatic pancreatic cancer,Optimised,"Optimised recommendation for nab‑paclitaxel with gemcitabine only if:

•other combination chemotherapies are unsuitable and they would otherwise have gemcitabine monotherapy and

•the company provides nab‑paclitaxel with the discount agreed in the patient access scheme.

"
761,TA478,2017/18,STA,Brentuximab vedotin ,Pharmaceutical,Relapsed or refractory systemic anaplastic large cell lymphoma,Optimised,"Optimised recommendation for brentuximab vedotin as an option for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if:
•they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and
•the company provides brentuximab vedotin according to the commercial access agreement with NHS England."
784,TA483,2017/18,STA,Nivolumab ,Pharmaceutical,Previously treated squamous non-small-cell lung cancer,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy, only if:
•nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and
•the conditions in the managed access agreement are followed.
"
785,TA484,2017/18,STA,Nivolumab ,Pharmaceutical,Previously treated non-squamous non-small-cell lung cancer,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer in adults after chemotherapy, only if:
•their tumours are PD‑L1 positive and
•nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and
•the conditions in the managed access agreement are followed."
791,TA487,2017/18,STA,Venetoclax ,Pharmaceutical,Chronic lymphocytic leukaemia,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating chronic lymphocytic leukaemia, that is, in adults:
•with a 17p deletion or TP53 mutation and when a B‑cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B‑cell receptor pathway inhibitor or
•without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo‑immunotherapy and a B‑cell receptor pathway inhibitor and
•only if the conditions in the managed access agreement are followed
"
792,TA488,2017/18,STA,Regorafenib ,Pharmaceutical,Previously treated unresectable or metastatic gastrointestinal stromal tumours,Optimised,"Optimised recommendation for regorafenib as an option for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib, only if:
•their Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1 and
•the company provides regorafenib with the discount agreed in the patient access scheme."
793,TA489,2017/18,STA,Vismodegib,Pharmaceutical,Basal cell carcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
794,TA490,2017/18,STA,Nivolumab,Pharmaceutical,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy ,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum-based chemotherapy, only if:
•the disease has progressed within 6 months of having chemotherapy
•nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression and
•the conditions in the managed access agreement are followed."
795,TA491,2017/18,STA,Ibrutinib ,Pharmaceutical,Waldenstrom’s macroglobulinaemia,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 prior therapy, only if the conditions in the managed access agreement for ibrutinib are followed."
796,TA492,2017/18,STA,Atezolizumab,Pharmaceutical,Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed."
799,TA495,2017/18,STA,"Palbocicli, with an aromatase inhibitor",Pharmaceutical,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
800,TA496,2017/18,STA,Ribociclib with an aromatase inhibitor,Pharmaceutical,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
802,TA498,2017/18,STA,Lenvatinib plus everolimus ,Pharmaceutical,Previously treated advanced renal cell carcinoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
804,TA500,2017/18,STA,Ceritinib,Pharmaceutical,Untreated ALK-positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
805,TA501,2017/18,MTA,Intrabeam radiotherapy system ,Pharmaceutical,Adjuvant treatment of early breast cancer,Only in Research,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Use of the Intrabeam radiotherapy system is recommended only using machines that are already available and in conjunction with NHS England specified clinical governance, data collection and submission arrangements."
806,TA502,2017/18,STA,Ibrutinib,Pharmaceutical,Relapsed or refractory mantle cell lymphoma,Optimised,"Optimised recommendation for ibrutinib as an option for treating relapsed or refractory mantle cell lymphoma in adults, only if:
•they have had only 1 previous line of therapy and
•the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England.
"
807,TA503,2017/18,STA,Fulvestrant ,Pharmaceutical,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
809,TA505,2017/18,STA,Ixazomib with lenalidomide and dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Optimised (CDF),"Optimised recommendation for ixazomib, with lenalidomide and dexamethasone,  for use within the Cancer Drugs Fund as an option for treating multiple myeloma in adults only if:
•they have already had 2 or 3 lines of therapy and
•the conditions in the managed access agreement for ixazomib are followed."
813,TA509,2017/18,STA,Pertuzumab in combination with trastuzumab and docetaxel,Pharmaceutical,HER2-positive breast cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
814,TA510,2017/18,STA, Daratumumab monotherapy ,Pharmaceutical,Relapsed and refractory multiple myeloma,Optimised (CDF),"Optimised recommendation for  daratumumab monotherapy for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults whose previous therapy included a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last therapy, only if:
•they have daratumumab after 3 previous therapies and
•the conditions in the managed access agreement are followed."
816,TA512,2017/18,STA,Tivozanib ,Pharmaceutical,Advanced renal cell carcinoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
817,TA513,2017/18,STA,Obinutuzumab ,Pharmaceutical,Untreated advanced follicular lymphoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
818,TA514,2017/18,STA,Regorafenib ,Pharmaceutical,Previously treated advanced hepatocellular carcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
819,TA515,2017/18,STA,Eribulin ,Pharmaceutical,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
820,TA516,2017/18,STA,Cabozantinib ,Pharmaceutical,Medullary thyroid cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
821,TA517,2018/19,STA,Avelumab (second-line and beyond treatment),Pharmaceutical,Metastatic Merkel cell carcinoma,Recommended,Recommended in line with marketing authorisation 
822,TA517,2018/19,STA,Avelumab (first-line),Pharmaceutical,Metastatic Merkel cell carcinoma,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating metastatic Merkel cell carcinoma in adults, only if:
•they have not had chemotherapy for metastatic disease and
•the conditions in the managed access agreement for avelumab are followed."
824,TA519,2018/19,STA,Pembrolizumab,Pharmaceutical,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, only if:
•pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier in the event of disease progression and
•the conditions in the managed access agreement for pembrolizumab are followed."
825,TA520,2018/19,STA,Atezolizumab ,Pharmaceutical,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,Optimised,"Optimised recommendation for atezolizumab as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour), only if:
•atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and
•the company provides atezolizumab with the discount agreed in the patient access scheme."
827,TA522,2018/19,STA,Pembrolizumab,Pharmaceutical,Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable, only if:
•pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and
•the conditions of the managed access agreement for pembrolizumab are followed."
828,TA523,2018/19,STA,Midostaurin ,Pharmaceutical,Untreated acute myeloid leukaemia,Recommended,Recommended in line withmarketing authorisation and following agreement of a patient access scheme.
829,TA524,2018/19,STA,Brentuximab vedotin ,Pharmaceutical,CD30-positive Hodgkin lymphoma,Optimised,"Optimised recommendation for brentuximab vedotin as an option for treating CD30‑positive Hodgkin lymphoma in adults with relapsed or refractory disease, only if:
•they have already had autologous stem cell transplant or
•they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable and
•the company provides brentuximab vedotin according to the patient access scheme"
830,TA525,2018/19,STA,Atezolizumab ,Pharmaceutical,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
831,TA526,2018/19,STA,Arsenic trioxide ,Pharmaceutical,Acute promyelocytic leukaemia,Recommended,Recommended in line with marketing authorisation.
836,TA528,2018/19,STA,Niraparib,Pharmaceutical,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",Optimised (CDF),"Optimised recommendation for niraparib for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults, only if:
•they have a germline BRCA mutation and have had 2 courses of platinum-based chemotherapy or
•they do not have a germline BRCA mutation and have had 2 or more courses of platinum-based chemotherapy and
•the conditions in the managed access agreement for niraparib are followed."
837,TA529,2018/19,STA,Crizotinib,Pharmaceutical,ROS1-positive advanced non-small-cell lung cancer,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating ROS1‑positive advanced non-small-cell lung cancer (NSCLC) in adults, only if the conditions in the managed access agreement are followed."
838,TA530,2018/19,STA,Nivolumab,Pharmaceutical,Locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
839,TA531,2018/19,STA,Pembrolizumab,Pharmaceutical,Untreated PD-L1-positive metastatic non-small-cell lung cancer,Recommended,Recommended in line with clinical practice and following agreement of a commercial access agreement.
843,TA535,2018/19,MTA,Lenvatinib,Pharmaceutical,Thyroid cancer,Optimised,"Optimised recommendation for lenvatinib as an option for treating thyroid cancer in adults whose disease does not respond to radioactive iodine, only if:
• they have not had a tyrosine kinase inhibitor before or
• they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification)
• the company provides lenvatinib according to the patient access scheme
"
844,TA535,2018/19,MTA,Sorafenib,Pharmaceutical,Thyroid cancer,Optimised,"Optimised recommendation for sorafenib as an option for treating thyroid cancer in adults whose disease does not respond to radioactive iodine, only if:
• they have not had a tyrosine kinase inhibitor before or
• they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification)
• the compay provides sorafenib according to the commercial access agreement
"
845,TA536,2018/19,STA,Alectinib,Pharmaceutical,Non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
849,TA538,2018/19,STA,Dinutuximab,Pharmaceutical,Neuroblastoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
850,TA539,2018/19,MTA,Lutetium (177Lu) oxodotreotide,Pharmaceutical,Unresectable or metastatic pancreatic neuroendocrine tumours,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
851,TA539,2018/19,MTA,Lutetium (177Lu) oxodotreotide,Pharmaceutical,Unresectable or metastatic gastrointestinal neuroendocrine tumours,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
852,TA540,2018/19,STA,Pembrolizumab,Pharmaceutical,Relapsed or refractory classical Hodgkin lymphoma,Optimised (CDF),"Optimised recommendation for pembrolizumab for use within the Cancer Drugs Fund as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had brentuximab vedotin and cannot have autologous stem cell transplant, only if:
•pembrolizumab is stopped after 2 years of treatment or earlier if the person has a stem cell transplant or the disease progresses and
•the conditions in the managed access agreement for pembrolizumab are followed"
853,TA541,2018/19,STA,Inotuzumab,Pharmaceutical,Relapsed or refractory B-cell acute lymphoblastic leukaemia,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
854,TA542,2018/19,STA,Cabozantinib,Pharmaceutical,Untreated advanced renal cell carcinoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
857,TA544,2018/19,STA,Dabrafenib with trametinib,Pharmaceutical,Resected BRAF V600 mutation-positive melanoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
858,TA545,2018/19,STA,Gemtuzumab ozogamicin with daunorubicin and cytarabine,Pharmaceutical,Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above,Optimised,Recommended in line with clinical practice and following agreement of a patient access scheme.
859,TA546,2018/19,STA,Padeliporfin ,Pharmaceutical,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
861,TA548,2018/19,STA,Decitabine,Pharmaceutical,Untreated acute myeloid leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
862,TA549,2018/19,STA,Denosumab,Pharmaceutical,Preventing skeletal-related events in multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
863,TA550,2018/19,STA,Vandetanib,Pharmaceutical,Medullary thyroid cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
864,TA551,2018/19,STA,Lenvatinib,Pharmaceutical,Untreated advance hepatocellular carcinoma,Optimised,Recommended in line with clinical practice and following agreement of a patient access scheme.
865,TA552,2018/19,STA,Liposomal cytarabine–daunorubicin ,Pharmaceutical,Untreated acute myeloid leukaemia,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
866,TA553,2018/19,STA,Pembrolizumab ,Pharmaceutical,Melanoma with high risk of recurrence,Recommended (CDF),Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of stage III melanoma with lymph node involvement in adults who have had complete resection. It is recommended only if the conditions in the managed access agreement for pembrolizumab are followed.
867,TA554,2018/19,STA,Tisagenlecleucel ,Pharmaceutical,Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years,Recommended (CDF),"Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B‑cell acute lymphoblastic leukaemia in people aged up to 25 years, only if the conditions in the managed access agreement are followed."
868,TA555,2018/19,STA,Regorafenib ,Pharmaceutical,Previously treated advanced hepatocellular carcinoma,Optimised,Recommended in line with clinical practice and following agreement of a patient access scheme.
870,TA557,2018/19,STA,Pembrolizumab ,Pharmaceutical,"Untreated, metastatic, non-squamous non-small-cell lung cancer",Optimised (CDF),"Pembrolizumab, with pemetrexed and platinum chemotherapy is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. It is only recommended if: •pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses and
•the company provides pembrolizumab according to the managed access agreement."
871,TA558,2018/19,STA,Nivolumab,Pharmaceutical,Completely resected melanoma with lymph node involvement or metastatic disease,Recommended (CDF),Nivolumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. It is recommended only if the conditions in the managed access agreement are followed.
872,TA559,2018/19,STA,Axicabtagene ciloleucel ,Pharmaceutical,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,Recommended (CDF),"Axicabtagene ciloleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B‑cell lymphoma or primary mediastinal large B‑cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed."
873,TA560,2018/19,STA,Bevacizumab ,Pharmaceutical,First recurrence of platinum-sensitive advanced ovarian cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
874,TA561,2018/19,STA,Venetoclax ,Pharmaceutical,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
875,TA562,2018/19,STA,Encorafenib ,Pharmaceutical,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme. There are patient access schemes for encorafenib and binimetinib
876,TA563,2018/19,STA,Abemaciclib,Pharmaceutical,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",Recommended,Recommended in line with marketing authorisation and only if company provides it according to the commercial agreement
877,TA564,2018/19,STA,Dabrafenib ,Pharmaceutical,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
882,TA567,2018/19,STA,Tisagenlecleucel ,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies,Recommended (CDF),"Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed."
884,TA569,2018/19,STA,Pertuzumab ,Pharmaceutical,Adjuvant treatment of HER2-positive early stage breast cancer,Optimised,"Pertuzumab, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults, only if:
•they have lymph node-positive disease
•the company provides it according to the commercial arrangement.
"
885,TA570,2018/19,STA,Pembrolizumab ,Pharmaceutical,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
886,TA571,2018/19,STA,Brigatinib,Pharmaceutical,ALK-positive advanced non-small-cell lung cancer after crizotinib,Recommended,Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
889,TA573,2019/20,STA,Daratumumab,Pharmaceutical,Multiple myeloma,Recommended (CDF),Recommended in the CDF
892,TA576,2019/20,STA,Bosutinib,Pharmaceutical,Chronic myeloid leukaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
893,TA577,2019/20,STA,Brentuximab vedotin ,Pharmaceutical,CD30-positive cutaneous T-cell lymphoma,Optimised,"Optimised recommendation for brentuximab vedotin for treating CD30‑positive cutaneous T‑cell lymphoma after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome "
894,TA578,2019/20,STA,Durvalumab ,Pharmaceutical,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,Recommended (CDF),"Durvalumab monotherapy is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express PD‑L1 on at least 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation only if:
•they have had concurrent platinum-based chemoradiation
•the conditions in the managed access agreement are followed.
"
895,TA579,2019/20,STA,Abemaciclib ,Pharmaceutical,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Recommended (CDF),"Abemaciclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in people who have had endocrine therapy only if:
•exemestane plus everolimus would be the most appropriate alternative and
•the conditions in the managed access agreement for abemaciclib with fulvestrant are followed.
"
896,TA580,2019/20,STA,Enzalutamide ,Pharmaceutical,Hormone-relapsed non-metastatic prostate cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
897,TA581,2019/20,STA,Nivolumab with ipilimumab,Pharmaceutical,Untreated advanced renal cell carcinoma,Recommended (CDF),Nivolumab with ipilimumab is recommended for use within the Cancer Drugs Fund as an option for adults with untreated advanced renal cell carcinoma that is intermediate- or poor-risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria. It is recommended only if the conditions in the managed access agreement for nivolumab with ipilimumab are followed.
898,TA582,2019/20,STA,Cabozantinib ,Pharmaceutical,Previously treated advanced hepatocellular carcinoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
900,TA584,2019/20,STA,"Atezolizmab with bevacizumab, paclitaxel and carboplatin",Pharmaceutical,First-line treatment of metastatic non-squamous non-small cell lung cancer ,Recommended,"Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults:
•who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49% or
•when targeted therapy for epidermal growth factor receptor (EGFR)‑positive or anaplastic lymphoma kinase (ALK)‑positive NSCLC has failed.
It is only recommended if:
•atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if there is loss of clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab) and
•he company provides atezolizumab and bevacizumab according to the commercial arrangements
"
902,TA586,2019/20,STA,Lenalidomide with dexamethasone,Pharmaceutical,Multiple myeloma in adults who have hade at least one prior therapy,Optimised,"Optimised recommendation for lenalidomide plus dexamethasone for treating multiple myeloma in adults only if: they have only 1 previous therapy, which included bortezomib"
903,TA587,2019/20,STA,Lenalidomide with dexamethasone,Pharmaceutical,Previously untreated multiple myeloma who are not eligible for transplant,Optimised,"Optimised recommendation for lenalidomide plus dexamethasone for previously untreated multiple myeloma in adults who are not eligible for a stem cell transplant, only if:
•thalidomide is contraindicated (including for pre-existing conditions that it may aggravate) or
•the person cannot tolerate thalidomide"
905,TA589,2019/20,STA,Blinatumomab ,Pharmaceutical,Acute lymphoblastic leukaemia in remission with minimal residual disease activity,Optimised,"Optimised recommendation for blinatumomab for treating Philadelphia-chromosome-negative CD19‑positive B‑precursor acute lymphoblastic leukaemia in adults with minimal residual disease (MRD) of at least 0.1%, only if:
• the disease is in first complete remission and
• the company provides blinatumomab according to the commercial arrangement
"
908,TA592,2019/20,STA,Cemiplimab ,Pharmaceutical,Metastatic or locally advanced cutaneous squamous cell carcinoma,Recommended (CDF),"Cemiplimab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not appropriate. It is recommended only if the conditions in the managed access agreement are followed.

Treatment with cemiplimab should be continued until disease progression or for up to 24 months (whichever is sooner)."
909,TA593,2019/20,STA,Ribociclib with fulvestrant,Pharmaceutical,"Hormone receptor-positive, HER2-negative, advanced breast cancer",Optimised (CDF),"Ribociclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy only if:
• exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor and
• the conditions in the managed access agreement for ribociclib with fulvestrant are followed.
"
910,TA594,2019/20,STA,Brentuximab vedotin ,Pharmaceutical,Untreated advanced Hodgkin lymphoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
911,TA595,2019/20,STA,Dacomitinib ,Pharmaceutical,Untreated EGFR mutation-positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
914,TA598,2019/20,STA,Olaparib ,Pharmaceutical,"Advanced ovarian, fallopian tube or peritoneal cancer",Recommended (CDF),"Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for olaparib are followed."
916,TA600,2019/20,STA,Pembrolizumab with carboplatin and paclitaxel,Pharmaceutical,Untreated metastatic squamous non-small-cell lung cancer,Recommended (CDF),"Pembrolizumab, with carboplatin and paclitaxel, is recommended for use within the Cancer Drugs Fund as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults only if:
•pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and
•the company provides pembrolizumab according to the managed access agreement
"
918,TA602,2019/20,STA,Pomalidomide with bortezomib and dexamethasone ,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
919,TA603,2019/20,STA,Lenalidomide with bortezomib and dexamethasone,Pharmaceutical,Untreated multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
920,TA604,2019/20,STA,Idelalisib ,Pharmaceutical,Refractory follicular lymphoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
924,TA608,2019/20,STA,Ibrutinib with rituximab ,Pharmaceutical, Waldenstrom’s macroglobulinaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
925,TA609,2019/20,STA,Ramucirumab ,Pharmaceutical,Unresectable hepatocellular carcinoma after sorafenib,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
927,TA611,2019/20,STA,Rucaparib,Pharmaceutical,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Recommended (CDF),"Rucaparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, only if the conditions in the managed access agreement for rucaparib are followed."
928,TA612,2019/20,STA,Neratinib ,Pharmaceutical,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",Optimised,"Optimised recommendation for neratinib for the extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑positive early stage breast cancer in adults who completed adjuvant trastuzumab-based therapy less than 1 year ago only if:
•trastuzumab is the only HER2‑directed adjuvant treatment they have had, and
•if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the breast or axilla following the neoadjuvant treatment, and
•the company provides neratinib according to the commercial arrangement.
"
934,TA618,2019/20,STA,Atezolizumab with carboplatin and nab-paclitaxel ,Pharmaceutical,Untreated advanced non-squamous non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
935,TA619,2019/20,STA,Palbociclib with fulvestrant,Pharmaceutical," Hormone receptor-positive, HER2-negative, advanced breast cancer",Recommended (CDF),"Palbociclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy only if:
•exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor and
•the conditions in the managed access agreement for palbociclib with fulvestrant are followed."
936,TA620,2019/20,STA,Olaparib ,Pharmaceutical,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Optimised,"Optimised recommendation for  olaparib for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy only if:
•they have a BRCA1 or BRCA2 mutation
•they have had 3 or more courses of platinum-based chemotherapy and
•the company provides olaparib according to the commercial arrangement."
937,TA620,2019/20,STA,Olaparib,Pharmaceutical,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Optimised (CDF),"Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy only if:
•they have a BRCA1 or BRCA2 mutation
•they have had 2 courses of platinum-based chemotherapy and
•the conditions in the managed access agreement for olaparib are followed.
"
938,TA621,2019/20,STA,Osimertinib,Pharmaceutical,Untreated EGFR mutation-positive non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
943,TA627,2020/21,STA,Lenalidomide with rituximab,Pharmaceutical,Previously treated follicular lymphoma,Recommended,Recommmended in line with marketing autorisation
944,TA628,2020/21,STA,Lorlatinib ,Pharmaceutical,Previously treated ALK-positive advanced non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
945,TA629,2020/21,STA,Obinutuzumab with bendamustine ,Pharmaceutical,Follicular lymphoma after rituximab,Recommended,Recommended in line with marketing autorisation
946,TA630,2020/21,STA,Larotrectinib ,Pharmaceutical,NTRK fusion-positive solid tumours,Recommended (CDF),"Larotrectinib is recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children if:
•the disease is locally advanced or metastatic or surgery could cause severe health problems and
•they have no satisfactory treatment options.
It is recommended only if the conditions in the managed access agreement for larotrectinib are followed.
"
949,TA632,2020/21,STA,Trastuzumab emtansine,Pharmaceutical,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",Recommended,"Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy. It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement"
951,TA634,2020/21,STA,Daratumumab with lenalidomide and dexamethasone,Pharmaceutical,Untreated multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
952,TA635,2020/21,STA,Ramucirumab with erlotinib,Pharmaceutical,Untreated EGFR mutation-positive non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
955,TA638,2020/21,STA,Atezolizumab with carboplatin and etoposide ,Pharmaceutical,Untreated extensive-stage small-cell lung cancer,Optimised,"Optimised recommendation for untreated extensive-stage small-cell lung cancer in adults, only if:
•they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and
• the company provides atezolizumab according to the commercial arrangement.
"
956,TA639,2020/21,STA,Atezolizumab with nab-paclitaxel ,Pharmaceutical,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",Recommended,Recommended in line with marketing autorisation
958,TA641,2020/21,STA,Brentuximab vedotin in combination ,Pharmaceutical,Untreated systemic anaplastic large cell lymphoma,Recommended,Recommended in line with marketing authorisation
959,TA642,2020/21,STA,Gilteritinib ,Pharmaceutical,Relapsed or refractory acute myeloid leukaemia,Optimised,"Optimsed recommendation for treating relapsed or refractory FLT3‑mutation-positive acute myeloid leukaemia (AML) in adults only if the company provides gilteritinib according to the commercial arrangement. 
Gilteritinib should not be given as maintenance therapy after a haematopoietic stem cell transplant."
960,TA643,2020/21,STA,Entrectinib ,Pharmaceutical,ROS1-positive advanced non-small-cell lung cancer,Recommended,Recommended in line with marketing autorisation
961,TA644,2020/21,STA,Entrectinib ,Pharmaceutical,NTRK fusion-positive solid tumours,Recommended (CDF),"Entrectinib is recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if:
•the disease is locally advanced or metastatic or surgery could cause severe health problems and
•they have not had an NTRK inhibitor before and
•they have no satisfactory treatment options.
It is recommended only if the conditions in the managed access agreement for entrectinib are followed.
"
962,TA645,2020/21,STA,Avelumab with axitinib for untreated advanced renal cell carcinoma,Pharmaceutical,Untreated advanced renal cell carcinoma,Recommended (CDF),Avelumab with axitinib is recommended for use within the Cancer Drugs Fund as an option for untreated advanced renal cell carcinoma in adults. It is recommended only if the conditions in the managed access agreement for avelumab with axitinib are followed.
963,TA646,2020/21,STA,Glasdegib,Pharmaceutical,Untreated acute myeloid leukaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
966,TA649,2020/21,STA,Polatuzumab vedotin with rituximab and bendamustine,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma,Recommended,Recommended in line with marketing autorisation
967,TA650,2020/21,STA,Pembrolizumab with axitinib ,Pharmaceutical,Untreated advanced renal cell carcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
969,TA652,2020/21,STA,Alpelisib with fulvestrant ,Pharmaceutical,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
970,TA653,2020/21,STA,Osimertinib,Pharmaceutical,EGFR T790M mutation-positive advanced non-small-cell lung cancer,Optimised,"Optimised recommendation for  treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults, only if:
• their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor and
• the company provides osimertinib according to the commercial arrangement."
971,TA654,2020/21,STA,Osimertinib ,Pharmaceutical,Untreated EGFR mutation-positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
972,TA655,2020/21,STA,Nivolumab,Pharmaceutical, Advanced squamous non-small-cell lung cancer after chemotherapy,Optimised,"Optimsed recommendation for treating locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if: 
• it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses and
• they have not had a PD‑1 or PD‑L1 inhibitor before. 
It is recommended only if the company provides nivolumab according to the commercial arrangement. 
"
974,TA657,2020/21,STA,Carfilzomib for previously treated multiple myeloma,Pharmaceutical,Previously treated multiple myeloma,Recommended,"Reissue of TA457 to allow previous treatment with bortezomib since clincial practiac has changed. Recommendations now read:
Carfilzomib with dexamethasone is recommended as an option for treating multiple myeloma in adults, only if: 
•they have had only 1 previous therapy and
•the company provides carfilzomib according to the commercial arrangement."
975,TA658,2020/21,STA,Isatuximab with pomalidomide and dexamethasone ,Pharmaceutical,Relapsed and refractory multiple myeloma,Recommended (CDF),"Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed on their last treatment, only if:
•they have had 3 previous lines of treatment
•the conditions in the managed access agreement for isatuximab plus pomalidomide and dexamethasone are followed.
"
977,TA660,2020/21,STA,Darolutamide with androgen deprivation therapy ,Pharmaceutical,Hormone-relapsed non-metastatic prostate cancer,Recommended,Recommended in line with the marketing autorisation and only if company provides it according to the patient access scheme
978,TA661,2020/21,STA,Pembrolizumab ,Pharmaceutical,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,Optimised,"Optimised recommendation for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD‑L1 with a combined positive score (CPS) of 1 or more. This is only if:
•pembrolizumab is given as a monotherapy
•pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and
•the company provides pembrolizumab according to the commercial arrangement.
"
979,TA662,2020/21,STA,Durvalumab in combination ,Pharmaceutical,Untreated extensive-stage small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
980,TA663,2020/21,STA,Venetoclax with obinutuzumab ,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for adults only if:
•there is a 17p deletion or TP53 mutation, or
•there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR), is unsuitable, and
•the companies provide the drugs according to the commercial arrangements."
981,TA663,2020/21,STA,Venetoclax with obinutuzumab ,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Recommended (CDF),"Venetoclax plus obinutuzumab is recommended for use within the Cancer Drugs Fund as an option for untreated CLL in adults, only if:
•there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and
•the conditions in the managed access agreement for venetoclax plus obinutuzumab are followed."
987,TA666,2020/21,STA,Atezolizumab with bevacizumab ,Pharmaceutical,Advanced or unresectable hepatocellular carcinoma,Optimised,"Optimsed recommendation for Atezolizumab plus bevacizumab for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment, only if:
•they have Child‑Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and
•the company provides it according to the commercial arrangement.
"
989,TA668,2020/21,STA,Encorafenib plus cetuximab ,Pharmaceutical,Previously treated BRAF V600E mutation-positive metastatic colorectal cancer,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the commercial access agreement
990,TA669,2020/21,STA,Trifluridine–tipiracil ,Pharmaceutical,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
991,TA670,2020/21,STA,Brigatinib ,Pharmaceutical,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor ,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
994,TA673,2020/21,STA,Niraparib ,Pharmaceutical,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",Recommended (CDF),"Niraparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for niraparib are followed."
995,TA674,2020/21,STA,Pembrolizumab,Pharmaceutical,"Untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable",Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1002,TA677,2020/21,STA,Autologous anti-CD19-transduced CD3+ cells,Pharmaceutical,Relapsed or refractory mantle cell lymphoma ,Recommended (CDF),Treatment with autologous anti-CD19-transduced CD3+ cells is recommended for use within the Cancer Drugs Fund as an option for relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton's tyrosine kinase (BTK) inhibitor. It is only recommended if the conditions in the managed access agreement for autologous anti‑CD19‑transduced CD3+ cells treatment are followed. 
1004,TA680,2020/21,STA,Lenalidomide ,Pharmaceutical,Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,Optimised,"Optimised recommendation for lenalidomide as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults, only if:
•the dosage schedule is 10 mg per day on days 1 to 21 of a 28‑day cycle and
•the company provides lenalidomide according to the commercial arrangement.
NOTE: The use of lenalidomide as a maintenance treatment after an autologous stem cell transplant at a dosage of 10 mg per day on days 1 to 21 of a 28-day cycle is outside the terms of the marketing authorisation for lenalidomide. Consequently, the statutory funding requirement does not apply to this recommendation. "
1007,TA683,2020/21,STA,Pembrolizumab with pemetrexed and platinum chemotherapy ,Pharmaceutical,"Untreated, metastatic, non-squamous non-small-cell lung cancer",Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the commerical access agreement
1008,TA684,2020/21,STA,Nivolumab ,Pharmaceutical,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
1010,TA686,2020/21,STA,Blinatumomab,Pharmaceutical, Previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1011,TA687,2020/21,STA,Ribociclib with fulvestrant ,Pharmaceutical,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Recommended,CDF review of TA593
1012,TA688,2020/21,MTA,Selective internal radiation therapy SIR-Spheres,Pharmaceutical,Hepatocellular carcinoma,Optimised,"Optimsed recommendation selective internal radiation therapy (SIRT) SIR‑Spheres for treating unresectable advanced hepatocellular carcinoma (HCC) in adults, only if:
•used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and
•the company provides SIR‑Spheres according to the commercial arrangement.
"
1013,TA688,2020/21,MTA,Selective internal radiation therapy TheraSphere,Pharmaceutical,Hepatocellular carcinoma,Optimised,"Olptimised recommendation for SIRT TheraSphere for treating unresectable advanced HCC in adults, only if:
•used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and
•the company provides TheraSphere according to the commercial arrangement.
"
1014,TA688,2020/21,MTA,Selective internal radiation therapy QuiremSpheres,Pharmaceutical,Hepatocellular carcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
1015,TA689,2021/22,STA,Acalabrutinib ,Pharmaceutical,Chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for untreated chronic lymphocytic leukaemia (CLL) in adults, only if:
• there is a 17p deletion or TP53 mutation, or
• there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable, and
• the company provides the drug according to the commercial arrangement.
"
1016,TA689,2021/22,STA,Acalabrutinib ,Pharmaceutical,Chronic lymphocytic leukaemia,Optimised,"Optimised recommendation: as monotherapy is recommended, within its marketing authorisation, as an option for previously treated CLL in adults. It is recommended only if the company provides the drug according to the commercial arrangement."
1018,TA691,2021/22,STA,Avelumab,Pharmaceutical, Untreated metastatic Merkel cell carcinoma,Recommended,CDF review of recommendation 1.2 of TA517: for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease
1019,TA692,2021/22,STA,Pembrolizumab ,Pharmaceutical,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Not recommended,"CDF review of TA519. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
1020,TA693,2021/22,STA,Olaparib plus bevacizumab,Pharmaceutical,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",Optimised (CDF),"Optimised CDF recommendation for maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when:
•there has been a complete or partial response after first-line platinum-based chemotherapy plus bevacizumab, and
•the cancer is associated with homologous recombination deficiency (HRD).
It is recommended only if the conditions in the managed access agreement for olaparib are followed.
"
1022,TA695,2021/22,STA,Carfilzomib with dexamethasone and lenalidomide,Pharmaceutical,Previously treated multiple myeloma,Optimised,"Optimised recommenation for treating multiple myeloma in adults, only if:
•they have had only 1 previous therapy, which included bortezomib, and
•the company provides carfilzomib according to the commercial arrangement.
"
1028,TA700,2021/22,STA,Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ,Pharmaceutical,Refractory multiple myeloma ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1030,TA702,2021/22,STA,Ibrutinib with obinutuzumab ,Pharmaceutical,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1031,TA703,2021/22,STA,Ibrutinib with rituximab ,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1032,TA704,2021/22,STA,Trastuzumab deruxtecan ,Pharmaceutical,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,Recommended (CDF),Trastuzumab deruxtecan is recommended for use within the Cancer Drugs Fund as an option for treating HER2‑positive unresectable or metastatic breast cancer in adults after 2 or more anti‑HER2 therapies. It is recommended only if the conditions in the managed access agreement are followed.
1033,TA705,2021/22,STA,Atezolizumab ,Pharmaceutical,Untreated advanced non-small-cell lung cancer,Recommended,Recommmended in line with the marketing authorisation and only if company provides it according to the patient access scheme
1035,TA707,2021/22,STA,Nivolumab ,Pharmaceutical,Previously treated unresectable advanced or recurrent oesophageal cancer,Recommended,Recommmended in line with the marketing auhtorisation and only if company provides it according to the commerical access agreement
1037,TA709,2021/22,STA,Pembrolizumab ,Pharmaceutical,Untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency,Optimised,"Optimised recommendation for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults, only if:
•pembrolizumab is stopped after 2 years and no documented disease progression, and
•the company provides pembrolizumab according to the commercial arrangement."
1040,TA712,2021/22,STA,Enzalutamide,Pharmaceutical,Hormone-sensitive metastatic prostate cancer,Recommended,Recommended in line with the marketing authorisation and only if company provides it according to the patient access scheme
1041,TA713,2021/22,STA,Nivolumab ,Pharmaceutical,Advanced non-squamous non-small-cell lung cancer after chemotherapy,Optimised,"CDF review of TA484. locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if:
•their tumours are PD-L1 positive, and
•it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses, and
• they have not had a PD-1 or PD-L1 inhibitor before.
It is recommended only if the company provides nivolumab according to the commercial arrangement.
"
1042,TA714,2021/22,STA,Dasatinib ,Pharmaceutical,Philadelphia-chromosome-positive acute lymphoblastic leukaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1049,TA716,2021/22,STA,Nivolumab with ipilimumab,Pharmaceutical,Previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency,Recommended,Recommmended in line with the marketing auhtorisation and only if company provides it according to the commerical access agreements
1050,TA717,2021/22,STA,Duvelisib,Pharmaceutical,Relapsed follicular lymphoma after 2 or more systemic therapies,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1053,TA720,2021/22,STA,Chlormethine gel,Pharmaceutical,Mycosis fungoides-type cutaneous T-cell lymphoma,Optimised,"Optimised recommendation for treating early stage (stage 1A, 1B, and 2A) mycosis fungoides-type cutaneous T‑cell lymphoma (MF‑CTCL) in adults, only if the company provides chlormethine gel according to the commercial arrangement."
1054,TA721,2021/22,STA,Abiraterone ,Pharmaceutical,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
1055,TA722,2021/22,STA,Pemigatinib ,Pharmaceutical,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,Recommended,Recommmended in line with the marketing auhtorisation and only if company provides it according to the patient access scheme
1057,TA724,2021/22,STA,Nivolumab with ipilimumab and chemotherapy ,Pharmaceutical,Untreated metastatic non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
1058,TA725,2021/22,STA,Abemaciclib with fulvestrant ,Pharmaceutical,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
1059,TA726,2021/22,STA,Daratumumab with pomalidomide and dexamethasone ,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1060,TA727,2021/22,STA,Isatuximab with carfilzomib and dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1063,TA730,2021/22,STA,Avapritinib ,Pharmaceutical,Unresectable or metastatic gastrointestinal stromal tumours,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1070,TA736,2021/22,STA,Nivolumab ,Pharmaceutical,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
1071,TA737,2021/22,STA,Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy ,Pharmaceutical,Untreated advanced oesophageal and gastro-oesophageal junction cancer,Recommended,Recommended in line with clinical practice and following agreement of a commerical access agreement.
1073,TA739,2021/22,STA,Atezolizumab,Pharmaceutical,Untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
1074,TA740,2021/22,STA,Apalutamide with androgen deprivation therapy,Pharmaceutical,High-risk hormone-relapsed non-metastatic prostate cancer,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
1075,TA741,2021/22,STA,Apalutamide with androgen deprivation therapy ,Pharmaceutical,Hormone-sensitive metastatic prostate cancer ,Optimised,"Optimised recommendation for treating hormone-sensitive metastatic prostate cancer in adults, only if: 
• docetaxel is not suitable 
• the company provides apalutamide according to the commercial arrangement "
1076,TA742,2021/22,STA,Selpercatinib,Pharmaceutical,Advanced thyroid cancer with RET alterations,Recommended (CDF),"Selpercatinib is recommended for use within the Cancer Drugs Fund, as an option for treating:
advanced RET fusion-positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib
advanced RET-mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after cabozantinib or vandetanib.
It is recommended only if the conditions in the managed access agreement are followed."
1080,TA745,2021/22,STA,NBTXR-3 ,Pharmaceutical,Advanced soft tissue sarcoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1081,TA746,2021/22,STA,Nivolumab ,Pharmaceutical,Resected oesophageal or gastro-oesophageal junction cancer,Recommended,Recommended in line with clinical practice and following agreement of a commerical access agreement.
1085,TA750,2021/22,STA,Olaparib ,Pharmaceutical,Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1089,TA754,2021/22,STA,Mogamulizumab ,Pharmaceutical,Previously treated  Sézary syndrome,Optimised,"Optimised recommendation for treating Sézary syndrome in adults who have had at least 1 systemic treatment. It is recommended only if the company provides mogamulizumab according to the commercial arrangement.
"
1090,TA754,2021/22,STA,Mogamulizumab ,Pharmaceutical,Previously treated mycosis fungoides ,Optimised,"Optimised recommendation for treating mycosis fungoides in adults, only if:
• their condition is stage 2B or above and they have had at least 2 systemic treatments and
• the company provides mogamulizumab according to the commercial arrangement."
1092,TA756,2021/22,STA,Fedratinib,Pharmaceutical,Disease-related splenomegaly or symptoms in myelofibrosis,Recommended (CDF),"Fedratinib is recommended for use within the Cancer Drugs Fund as an option for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults. It is recommended only if:
they have previously had ruxolitinib and
the conditions in the managed access agreement for fedratinib are followed."
1096,TA760,2021/22,STA,Selpercatinib ,Pharmaceutical,Previously treated RET fusion-positive advanced non-small-cell lung cancer,Recommended (CDF),"Selpercatinib is recommended for use within the Cancer Drugs Fund as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults who need systemic therapy after immunotherapy, platinum-based chemotherapy or both. It is recommended only if the conditions in the managed access agreement are followed."
1097,TA761,2021/22,STA,Osimertinib ,Pharmaceutical,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,Optimised (CDF),"Osimertinib is recommended for use within the Cancer Drugs Fund as adjuvant treatment after complete tumour resection in adults with stage 1b to 3a non‑small‑cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. It is recommended only if:
•osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity and
•the company provides osimertinib according to the managed access agreement."
1098,TA762,2021/22,STA,Olaparib ,Pharmaceutical,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1099,TA763,2021/22,STA,Daratumumab in combination ,Pharmaceutical,Multiple myeloma when a stem cell transplant is suitable,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1101,TA765,2021/22,STA,Venetoclax with azacitidine,Pharmaceutical, Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1102,TA766,2021/22,STA,Pembrolizumab,Pharmaceutical,Adjuvant treatment of completely resected stage 3 melanoma,Recommended,"Recommended in line with marketing authorisation and following agreement of a patient access scheme.
Replaces TA553"
1106,TA770,2021/22,STA,Pembrolizumab with carboplatin and paclitaxel ,Pharmaceutical,Untreated metastatic squamous non-small-cell lung cancer,Optimised,"Optimised recommendation for Pembrolizumab with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if
their tumours express PD‑L1 with a tumour proportion score of 0% to 49%
their tumours express PD‑L1 with a tumour proportion score of 50% or more and they need urgent clinical intervention
it is stopped at 2 years of uninterrupted treatment or earlier if their disease progresses and
the company provides pembrolizumab according to the commercial arrangement.
CDF review of TA600 "
1107,TA771,2021/22,STA,"Daratumumab with bortezomib, melphalan and prednisone",Pharmaceutical, Untreated multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1108,TA772,2021/22,STA,Pembrolizumab ,Pharmaceutical,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,Recommended,"Recommendded in line with marketing authorisation and following agreemenet of a commerical access agreement.
Extension to the MA in TA540"
1110,TA774,2021/22,STA,Lenalidomide ,Pharmaceutical,Relapsed or refractory mantle cell lymphoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1115,TA779,2021/22,STA,Dostarlimab,Pharmaceutical,Previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,Recommended (CDF),Dostarlimab is recommended for use within the Cancer Drugs Fund as an option for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy. It is recommended only if the conditions in the managed access agreement are followed.
1116,TA780,2021/22,STA,Nivolumab with ipilimumab ,Pharmaceutical,Untreated advanced renal cell carcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1117,TA781,2021/22,STA,Sotorasib ,Pharmaceutical,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,Recommended (CDF),"Sotorasib is recommended for use within the Cancer Drugs Fund as an option for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy. It is recommended only if the conditions in the managed access agreement for sotorasib are followed."
1118,TA782,2021/22,STA,Tagraxofusp,Pharmaceutical, Treating blastic plasmacytoid dendritic cell neoplasm ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1119,TA783,2022/23,STA,Daratumumab monotherapy for treating relapsed and refractory multiple myeloma,Pharmaceutical,Relapsed and refractory multiple myeloma,Optimised,"CDF review of TA510 Optimised recommenation for daratumumab monotherapy is recommended as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment, only if:
they have daratumumab after 3 treatments and
the company provides daratumumab according to the commercial arrangement."
1120,TA784,2022/23,STA,Niraparib,Pharmaceutical,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",Optimised,"CDF review of TA528. Optimised recommendation for niraparib for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults. It is recommended only if: 
they have a BRCA mutation and have had 2 courses of platinum-based chemotherapy, or they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy, and
the company provides it according to the commercial arrangement."
1121,TA785,2022/23,STA,Nivolumab with cabozantinib ,Pharmaceutical,Untreated advanced renal cell carcinoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1122,TA786,2022/23,STA,Tucatinib with trastuzumab and capecitabine ,Pharmaceutical,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
1123,TA787,2022/23,STA,Venetoclax with low dose cytarabine ,Pharmaceutical,Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Optimised,"Optimised recommendation for venetoclax with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable, only if:
they have over 30% bone marrow blasts
the company provides venetoclax according to the commercial arrangement."
1124,TA788,2022/23,STA,Avelumab ,Pharmaceutical,Maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy,Optimised,"Optimised recommendation for avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer that has not progressed after platinum-based chemotherapy in adults, only if:
avelumab is stopped at 5 years of uninterrupted treatment or earlier if the disease progresses and
the company provides avelumab according to the commercial arrangement."
1125,TA789,2022/23,STA,Tepotinib ,Pharmaceutical,Advanced non-small-cell lung cancer with MET gene alterations,Recommended,Recommended in line with the marketing authorisation and following agreement of a patient access scheme.
1131,TA795,2022/23,STA,Ibrutinib ,Pharmaceutical,Waldenstrom’s macroglobulinaemia,Not recommended,"CDF review of TA491. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
1132,TA796,2022/23,STA,Venetoclax ,Pharmaceutical,Chronic lymphocytic leukaemia,Recommended,CDF review of TA487 Recommended in line with the martketing authorisation and following agreement of a patient access schemem
1133,TA797,2022/23,STA,Enfortumab vedotin ,Pharmaceutical,Previously treated locally advanced or metastatic urothelial cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1134,TA798,2022/23,STA,Durvalumab ,Pharmaceutical,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,Optimised,"CDF review of TA578 Optimised recommendation for durvalumab for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD‑L1) on 1% or more of cells and whose disease has not progressed after platinum-based chemoradiation, only if:
they have had concurrent platinum-based chemoradiation
the company provides durvalumab according to the commercial arrangement."
1137,TA801,2022/23,STA,Pembrolizumab plus chemotherapy,Pharmaceutical," Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",Optimised,"Optimised recommendation for pembrolizumab plus chemotherapy (paclitaxel or nab‑paclitaxel) for treating triple‑negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease. It is recommended only if:
the tumours express PD‑L1 with a combined positive score (CPS) of 10 or more and an immune cell staining (IC) of less than 1%, and
the company provides pembrolizumab according to the commercial arrangement."
1138,TA802,2022/23,STA,Cemiplimab,Pharmaceutical,Advanced cutaneous squamous cell carcinoma,Optimised,"CDF review of TA592 Optimised recommendation for cemiplimabn for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not suitable, only if:
it is stopped at 24 months, or earlier if their disease progresses, and
the company provides cemiplimab according to the commercial arrangement."
1146,TA810,2022/23,STA,Abemaciclib with endocrine therapy ,Pharmaceutical,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",Recommended,"Recommended in line with marketing authorisation and following agreement of a patient access scheme. 
NB The MA is confuisng and split across section 4.1 and 5.1.
"
1147,TA811,2022/23,STA,Duvelisib ,Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1148,TA812,2022/23,STA,Pralsetinib ,Pharmaceutical,RET fusion-positive advanced non-small-cell lung cancer,Not recommended," At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
1149,TA813,2022/23,STA,Asciminib ,Pharmaceutical,Chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme. 
1154,TA816,2022/23,STA,Alpelisib with fulvestrant ,Pharmaceutical,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",Optimised,"Replaces TA652 Optimised recommendation for alpelisib plus fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults, only if:
their cancer has progressed after a CDK4/6 inhibitor plus an aromatase inhibitor and
the company provides alpelisib according to the commercial arrangement)."
1155,TA817,2022/23,STA,Nivolumab,Pharmaceutical,Invasive urothelial cancer at high risk of recurrence,Optimised,"Optimsed recommendation for nivolumab for the adjuvant treatment of muscle-invasive urothelial cancer that is at high risk of recurrence after radical resection in adults whose tumours express PD-L1 at a level of 1% or more. It is recommended only if:
adjuvant treatment with platinum‑based chemotherapy is unsuitable, and 
the company provides nivolumab according to the commercial arrangement."
1156,TA818,2022/23,STA,Nivolumab with ipilimumab ,Pharmaceutical,Untreated unresectable malignant pleural mesothelioma,Optimised,"Optimised recommendation for nivolumab plus ipilimumab is recommended as an option for untreated unresectable malignant pleural mesothelioma in adults, only if:
they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
the company provides it according to the commercial arrangement."
1157,TA819,2022/23,STA,Sacituzumab govitecan ,Pharmaceutical,Unresectable triple-negative advanced breast cancer after 2 or more therapies,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme. 
1161,TA823,2022/23,STA,Atezolizumab,Pharmaceutical,Adjuvant treatment of resected non-small-cell lung cancer,Recommended (CDF),"Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for adjuvant treatment after complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer (NSCLC) whose:
tumours have the programmed cell death ligand‑1 (PD‑L1) biomarker expression on 50% or more of their tumour cells and
whose disease has not progressed after platinum-based adjuvant chemotherapy.
It is recommended only if the company provides atezolizumab according to the managed access agreement."
1165,TA827,2022/23,STA,Oral azacitidine ,Pharmaceutical,Maintenance treatment of acute myeloid leukaemia after induction therapy,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme. 
1168,TA830,2022/23,STA,Pembrolizumab ,Pharmaceutical,Adjuvant treatment of renal cell carcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme. 
1169,TA831,2022/23,STA,Olaparib ,Pharmaceutical,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,Not recommended," At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
1174,TA836,2022/23,STA,Palbociclib with fulvestrant ,Pharmaceutical,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Recommended,CDF review of TA619. Recommended in line with clincial practice and following agreement of a patient access scheme.
1175,TA837,2022/23,STA,Pembrolizumab ,Pharmaceutical,Adjuvant treatment of resected stage 2B or 2C melanoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
1179,TA841,2022/23,STA,Carfilzomib with daratumumab and dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1180,TA842,2022/23,STA,Tisagenlecleucel ,Pharmaceutical,Follicular lymphoma after 2 or more therapies ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1186,TA848,2022/23,STA,Cemiplimab,Pharmaceutical,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
1187,TA849,2022/23,STA,Cabozantinib,Pharmaceutical, Previously treated advanced hepatocellular carcinoma,Optimised,"Replaces TA582. Optimised recommendation for cabozantinib for treating advanced hepatocellular carcinoma (HCC) in adults who have had sorafenib, only if:
they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and
the company provides it according to the commercial arrangement.
"
1188,TA850,2022/23,STA,Amivantamab,Pharmaceutical,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
1189,TA851,2022/23,STA,Pembrolizumab ,Pharmaceutical,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a commerical access arrangement
1190,TA852,2022/23,STA,Trifluridine–tipiracil,Pharmaceutical,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments,Recommended,Rapide review of TA669.  Recommended in line with marketing authorisation and following agreement of a patient access scheme
1193,TA855,2022/23,STA,Mobocertinib,Pharmaceutical,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
1195,TA857,2022/23,STA,Nivolumab with platinum- and fluoropyrimidine-based chemotherapy,Pharmaceutical," Untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma",Recommended,Recommended in line with marketing authorisation and following agreement of a commerical access arrangement
1196,TA858,2022/23,MTA,Lenvatinib,Pharmaceutical, Untreated advanced renal cell carcinoma,Optimised,"Optimised recommendation for lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma in adults, only if:
their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and
nivolumab with ipilimumab would otherwise be offered and
the companies provide lenvatinib and pembrolizumab according to the commercial arrangements."
1197,TA858,2022/23,MTA,Lenvatinib,Pharmaceutical, Untreated advanced renal cell carcinoma,Optimised,"Optimised recommendation for lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma in adults, only if:
their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and
nivolumab with ipilimumab would otherwise be offered and
the companies provide lenvatinib and pembrolizumab according to the commercial arrangements."
1201,TA862,2022/23,STA,Trastuzumab deruxtecan ,Pharmaceutical,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,Recommended (CDF),Trastuzumab deruxtecan is recommended with managed access as an option for treating HER2‑positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. It is only recommended if the conditions in the managed access agreement for trastuzumab deruxtecan are followed.
1204,TA865,2022/23,STA,Nivolumab with fluoropyrimidine- and platinum-based chemotherapy ,Pharmaceutical,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",Optimised,"Optimised recommendation for nivolumab with fluoropyrimidine-based and platinum-based combination chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% or more. It is recommended only if:
 - pembrolizumab plus chemotherapy is not suitable
 - the company provides nivolumab according to the commercial arrangement."
1205,TA866,2022/23,STA,Regorafenib ,Pharmaceutical,Previously treated metastatic colorectal cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
1209,TA870,2022/23,STA,Ixazomib with lenalidomide and dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Optimised,"Review of TA505. Optimised recommenation for ixazomib, with lenalidomide and dexamethasone, as an option for treating multiple myeloma in adults, only if:
they have had 2 or 3 lines of therapy and 
the company provides ixazomib according to the commercial arrangement."
1211,TA872,2022/23,STA,Axicabtagene ciloleucel ,Pharmaceutical,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,Recommended,CDF review of TA559. Recommended in line with marketing authorisation and following agreement of a patient access scheme
1215,TA876,2022/23,STA,Nivolumab with chemotherapy ,Pharmaceutical,Neoadjuvant treatment of resectable non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme